Research programme: cancer therapeutics - Genexine

Drug Profile

Research programme: cancer therapeutics - Genexine

Alternative Names: GX-02; GX-06

Latest Information Update: 02 Apr 2018

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Genexine
  • Class CAR-NK cell therapies; Immunotherapies
  • Mechanism of Action Immunomodulators; Natural killer cell replacements
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Discontinued Brain cancer; Breast cancer; Haematological malignancies; Skin cancer

Most Recent Events

  • 02 Apr 2018 Discontinued - Preclinical for Haematological malignancies in South Korea (unspecified route) (Genexine pipeline, March 2018)
  • 28 Mar 2018 Discontinued - Preclinical for Brain cancer in South Korea (Parenteral) (Genexine pipeline, March 2018)
  • 28 Mar 2018 Discontinued - Preclinical for Breast cancer in South Korea (Parenteral) (Genexine pipeline, March 2018)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top